Modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes within the lymph nodes. Here, we evaluated the potential of an agonist at this receptor, FTY720 (fingolimod), to activate the promyelinating pathways within the brain to encourage remyelination and neuroprotection.
Introduction
Demyelination is a characteristic histopathological finding in multiple sclerosis (MS). In addition, axonal and neuronal loss (i.e. neuronal degeneration) is an equally important disease characteristic (Back et al., 2005; Geurts and Barkhof, 2008; Geurts et al., 2009) . Remyelination, one of the most efficient endogenous repair processes within the CNS, maintains the structural integrity of the axon, restores axonal conduction properties and functio laesa following demyelination. For example, it has been found that proper conduction is restored with remyelination (Smith et al., 1979) and that demyelinated, but not remyelinated, lesions are characterized by acute axonal damage (Kornek et al., 2000) . Furthermore, experimental inhibition of remyelination in rodents results in a significant increase in the extent of axonal degeneration and loss (Irvine and Blakemore, 2008) , and extensive remyelination at the histopathological level correlates with functional recovery (Duncan et al., 2009) . The presence of shadow plaques, representing fully remyelinated lesions, demonstrate that complete repair of MS plaques is, in principle, possible (Prineas et al., 1984) , although it is common to observe only limited repair at the edge of lesions (Prineas and Connell, 1979) . It is not clear why, in some patients, remyelination is widespread while in others it is sparse, and understanding why a relatively robust regenerative process should lose momentum is an important prerequisite for developing an effective therapeutic approach . FTY720 (fingolimod), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral disease-modifying therapeutic agent to be approved for the treatment of MS. FTY720 is rapidly converted in vivo to the active S-fingolimodphosphate (FTY720-P) which binds to S1P receptors. This action inhibits emigration of lymphocytes from the lymph nodes preventing entry into the blood and thus infiltration into the CNS (Brinkmann et al., 2010; Kipp and Amor, 2012) . S1P receptors belong to the endothelial differentiation gene receptor family which is composed of eight different GPCRs. Preclinical studies have demonstrated that FTY720 exerts beneficial functions in studies of several experimental autoimmune encephalomyelitis (EAE) models (Fujino et al., 2003; Foster et al., 2007; Papadopoulos et al., 2010; Choi et al., 2011; Anthony et al., 2014) . In addition, clinical trials revealed that several aspects of MS disease activity, for example brain volume loss and disability progression, are suppressed in patients treated with FTY720 (Kappos et al., 2010; Radue et al., 2012) .
As mentioned, the efficacy of FTY720 in immunemediated diseases has been attributed to lymphocyte sequestration in secondary lymphoid organs and consequent inhibition of lymphocyte trafficking to target organs via the blood stream (Mandala et al., 2002) . Notably, the efficacy of FTY720 in MS and the related animal models may in part be due to additional, direct effects within the brain (Van Doorn et al., 2010; Choi et al., 2011) . In this context, it is important to note that S1P receptors are expressed by various brain intrinsic cell types, such as oligodendrocytes (Jaillard et al., 2005) , neurons (Kimura et al., 2007) and astrocytes (Wu et al., 2008; Van Doorn et al., 2010) , and therefore have the potential to regulate neuron and/or glia cell morphology, migration, process extension, cell growth, differentiation, apoptosis and/or survival. The observation that S1P receptor activity can regulate oligodendrocyte physiology was first reported over a decade ago, when S1P was shown to stimulate Ca 2+ responses in an oligodendrocyte cell line (Fatatis and Miller, 1996) . Furthermore, S1Ps regulate MAPK signalling in primary cultured oligodendrocytes (Hida et al., 1999) . It is thus a very attractive concept to postulate that FTY720 might exert additional beneficial effects on MS disease progression independent of its effect on T and B cells.
Various animal models are available to study operant pathways during myelin repair and to elaborate how pharmacological intervention can modulate these pathways. One frequently used model in remyelination research is that based on the toxin cuprizone (Acs et al., 2009; Kipp et al., 2009; . In this model, the capacity for remyelination depends on the initial exposure to cuprizone. After 5 (acute demyelination) or 12 weeks (chronic demyelination) of treatment with cuprizone, several regions, such as the white matter tract corpus callosum (CC), are severely demyelinated. While the myelin status of the CC significantly recovers after acute demyelination, endogenous remyelination is impaired and/or delayed after chronic cuprizone exposure Lindner et al., 2009) . Furthermore, axonal damage occurs in acute and chronic lesions. In this study, we have used the cuprizone model in mice to investigate the effects of FTY720 on remyelination and axonal damage by means of immunohistochemical analyses and gene expression studies. These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http:// www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 ( a,b Alexander et al., 2013a,b) Methods
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Animals, induction of demyelination and FTY720 treatment
All animal care and experimental procedures were formally approved by the Review Board for the Care of Animal Subjects of the district government (North Rhine-Westphalia, Germany). All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals McGrath et al., 2010) . A total of 72 animals were used in the experiments described here. C57BL/6 mice (Le Genest-Saint-Isle, Janvier, France) were bred and maintained in a pathogen-free environment with a maximum of five animals per cage. Animals underwent routine cage maintenance once a week and microbiological monitoring according to the Federation of European Laboratory Animal Science Associations recommendations. Food and water were available ad libitum. Demyelination was induced by feeding 8-week-old (19-21 g) male mice a diet containing 0.2% cuprizone [bis(cyclohexanone)oxaldihydrazone; Sigma-Aldrich Inc., St Louis, MO, USA] mixed into a ground standard rodent chow. Acute or chronic cuprizoneinduced demyelination was performed by feeding animals for 5 or 12 weeks respectively (Kipp et al., 2011) . After cuprizoneinduced demyelination, animals were randomly assigned to experimental groups. Animals were allowed to recover for 11 days after acute and for 28 days after chronic toxin-induced demyelination by feeding normal chow. During this recovery period, animals were treated daily (between 0800 and 1000 h) by oral gavage (volume 100 μL) with either vehicle (H 2O) or FTY720 (0.3 mg·kg −1 body weight). Two independent experiments were performed with at least four animals per experimental group if not stated otherwise.
Tissue preparation
Tissue preparation was performed as previously described (Kipp et al., 2011; Clarner et al., 2012) . For histological and immunohistochemical studies, mice were anaesthetized with ketamine (100 mg·kg ; i.p.), transcardially perfused with ice-cold PBS followed by transcardial perfusion with 3.7% paraformaldehyde solution (pH 7.4). After overnight post-fixation in the same fixative, brains were dissected, embedded in paraffin and then coronal sectioned into 5 μm sections at the levels 255-285 according to the mouse brain atlas by Sidman et al. (http://www.hms .harvard.edu/research/brain/atlas.html). Prior to transcardial perfusion, blood was sampled by the left ventricle and further processed for the quantification of FTY720 and FTY720-P levels as published previously (Brinkmann et al., 2002) . For gene expression studies and quantification of FTY720-P levels, tissues were dissected after PBS perfusion, immediately frozen in liquid nitrogen and kept at −80°C until used.
Gene expression analyses
Gene expression levels were measured using the reverse transcription real time-PCR technology (BioRad, Munich, Germany), SensiMix Plus SYBR and Fluorescein (Quantace, Bioline, Luckenwalde, Germany) and a standardized protocol as described previously by our group (Buschmann et al., 2012; Clarner et al., 2012) . Primer sequences and individual annealing temperatures are shown in Table 1 . Relative quantification was performed using the ΔΔCt method which results in ratios between target genes and the housekeeping reference gene hypoxanthine guanine phosphoribosyltransferase. Melting curves and gel electrophoresis of the PCR products were routinely performed to determine the specificity of the PCR reaction (data not shown).
Immunohistochemistry (IHC)
For IHC, sections were rehydrated, and if necessary unmasked by Tris/EDTA buffer (pH 9.0) or citrate (pH 6.0) heating, washed in PBS and incubated overnight (4°C) with the primary antibody diluted in blocking solution (serum of species in which the secondary antibody was raised). Antiproteolipid protein-1 (PLP, 1:5000, AbD Serotec, Bio-Rad, Pucheim, Germany) antibody was used to detect intact myelin; anti-oligodendrocyte transcription factor (OLIG2, 1:2000, Merck Millipore, Darmstadt, Germany) antibody was used to detect oligodendrocytes, whereas anti-glial fibrillary acidic protein (GFAP, 1:12000, EnCor Biotechnologie Inc, Gainesville, FL, USA) antibody was used to visualize astrocytes. Anti-ionized calcium-binding adaptor molecule-1 (IBA-1, 1:10000, Wako Chemicals GmbH, Neuss, Germany) antibody was used to detect microglia/macrophages and antiamyloid precursor protein (APP, 1:5000, Merck Millipore) antibody was used to detect acute axonal damage. The next day, slides were subsequently incubated with biotinylated secondary antibodies for 1 h, followed by peroxidase-coupled avidin-biotin complex (ABC kit, Vector Laboratories, Peterborough, UK) and treated with 3,3-diaminobenzidine (DAKO, Hamburg, Germany) as a peroxidase substrate. Luxol fast blue (LFB)/periodic acid-Schiff (PAS) stains were performed following established protocols (Acs et al., 2009) . Stained and processed sections were digitalized using a Nikon ECLIPSE E200 microscope (Nikon, Nikon Instruments, Düs-seldorf, Germany) equipped with a DS-Vi1 camera. The open source program ImageJ was used to determine chromogen intensity in experimental groups.
Immunofluorescence labelling
To assess axonal densities in the chronic groups, the antibody to 200 kD neurofilament heavy (NF200, 1:50, Abcam, Cambridge, UK) was used followed by fluorescence detection. To this end, sections were incubated with fluorescent anti-rabbit secondary antibodies (Alexa Fluor 568 goat IgG; Invitrogen, Darmstadt, Germany; 1:500) diluted in blocking solution.
Sections were then incubated with Hoechst 33342 (Invitrogen; 1:1000) diluted in PBS for the staining of cell nuclei. Stained and processed sections were digitalized using a Leica DMI 6000B fluorescence microscope working station equipped with a DFC 365FX camera (Leica, Wetzlar, Germany) . The open source program ImageJ was used to determine fluorescence intensity in experimental groups. To detect cellular distribution of APP + spheroids, we performed immunofluorescence double labelling as published previously (Baertling et al., 2010) . In these experiments, we used a goat polyclonal antibody raised against a peptide mapping within an internal region of NF-H (E-15, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; 1:100). For this analysis, processed sections were documented with the confocal laser microscope working station Zeiss LSM 7 Duo (Oberkochen, Germany).
Quantification of (immuno)-histochemical parameters
In order to evaluate demyelination in PLP-or LFB-stained sections, the magnitude of myelination was scored in the midline of the CC (CCm) between 100 and 0. To assess myelination in the cortex, the somatosensory area of the cortex was defined as the region of interest, and staging was performed in PLP-stained sections as published previously . A score of 100 is equivalent to the myelin status of a control untreated mouse, whereas zero is equivalent to a totally demyelinated region of interest. Two independent readers, who were unaware of the treatments, performed the scoring and the results were averaged (Acs et al., 2009; Kipp et al., 2011) . Quantification of axonal spheroids (APP staining) as well as oligodendrocyte (OLIG2 staining), astrocyte (GFAP staining) and microglia (IBA-1 staining) cell numbers was performed by manually counting the number of positive structures in the region of interest. Counting was performed using a Nikon Eclipse 55i (Nikon) and a 40x objective. Numbers are expressed as cells·mm . As another parameter for astrocyte and microglia activation, we determined the area covered by IBA-1 or GFAP staining, respectively, using the freely available ImageJ software. Results are expressed as relative area of the CCm (stained area in relation to non-stained area in percentage). Finally, hypertrophy of microglia cells was analysed by quantifying the mean area covered per microglia cell in IBA-1-stained sections using the area measurement tool integrated in the Nikon NIS Elements software (Version 3.22.14, Nikon).
Data analysis
All data are given as arithmetic means ± SEM. Differences between groups were statistically tested by ANOVA followed by a Tukey's post hoc multiple-range test using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) except for differences between myelin scoring (PLP-stained and LFB/ PAS) in cuprizone-treated animals. There, differences between groups were analysed with the non-parametric Kruskal-Wallis test followed by Dunn's post hoc test. To test whether hypertrophy of microglia cells was different between vehicle and FTY720-treated animals, a two-tailed Student's t-test was performed. P values < 0.05 were considered to be statistically significant.
Results
FTY720 is an orally available S1P receptor modulator and a pro-drug that is mainly phosphorylated by sphingosine kinase type 2 (Sphk2) to the biologically active metabolite FTY720-P (Kaneider et al., 2004) . In the first set of experiments, we analysed the potency of FTY720 to boost remyelination in the cuprizone model in mice. To this end, animals were fed cuprizone for 5 weeks to induce acute demyelination. During the 11 days of recovery period, animals received either vehicle or FYT720 in a concentration of 0.3 mg·kg −1 body weight. To confirm adequate drug absorption, blood levels of FTY720 and its active phosphorylated metabolite FTY720-P were quantified in placebo-and vehicle-treated animals. As demonstrated in Figure 1 , both FTY720 entities were not detectable in control and vehicle-treated animals, whereas a significant increase was evident in FTY720-treated animals. In treated animals, FTY720 and FTY720-P blood levels were 31.8 and 86.6 nM respectively ( Figure 1A) . We, furthermore, analysed the expression of genes known to be involved in FTY720 phosphorylation (i.e. Sphk2) and dephosphorylation [i.e. sphingosine 1-phosphate phosphatase 1 (Sgpp1) and phosphatidic acid phosphatase type 2B (Ppap2b)]. Gene expression analyses revealed that the key FTY720-metabolizing enzymes Sphk2 and Sgpp1 were stably expressed in the liver ( Figure 1B ) and brains ( Figure 1C ). The expression of Ppap2b, the second phosphatase involved in the equilibrium between FTY720 and FTY720-P (Mechtcheriakova et al., 2007) , was slightly induced in both compartments (P < 0.01).
It is well known that cuprizone treatment does not affect the integrity of the blood-brain barrier . In a separate set of experiments, we determined the ratio of FTY720/FTY720-P in blood and in brain tissue. To this end, control animals were treated with FTY720 for 5 days, blood and brain tissue harvested and FTY720/FTY720-P concentrations quantified. This analysis revealed that both molecular entities of FTY720 (FTY720 and FTY720-P) accumulated in the brains despite an intact blood-brain barrier. FTY720 levels were 12.4 times and FTY720-P levels 10.8 times higher in the brain, compared with those in the blood respectively (data not shown). In summary, the applied study protocol resulted in reproducible accumulation of active FTY720 (i.e. FTY720-P) within the brain parenchyma.
To address myelination capacity, we performed anti-PLP and LFB/PAS stains and evaluated staining intensity in the CCm (see Table 2 ). As demonstrated in Figure 2A by anti-PLP stain, severe demyelination (−70%) was evident in the CCm after acute cuprizone exposure. The magnitude of demyelination was more severe in LFB-stained sections (comparison of grey and white bars in Figure 2A ). Both stains revealed significant recovery of myelination 11 days after acute
Figure 1
Daily FTY720 treatment results in stable phosphorylated FTY720 (FTY720-P) blood levels. (A) Blood levels of phosphorylated and nonphosphorylated FTY720. (B) Expression levels of Sphk2, Ppap2b and Sgpp1 in liver tissues. (C) Expression levels of Sphk2, Ppap2b and Sgpp1 in CNS tissues after acute demyelination. Note constant expression of the two key FTY720-metabolizing enzymes Sphk2 and Sgpp1, paralleled by increased FTY720 and FTY720-P levels in FTY720-treated animals. **P < 0.01, significantly different from controls.
cuprizone-induced demyelination. The extent of remyelination was, however, not significantly higher in FTY720-compared with vehicle-treated animals. We furthermore tested the ability of FTY720 to boost remyelination in the cortex which is as well affected in this animal model (Skripuletz et al., 2008) . As demonstrated in Figure 2A (lower right side), significant cortical demyelination (−95%) was evident after acute cuprizone-induced demyelination. Remyelination in the cortex was delayed compared with the robust remyelination observed in the CC. However, the extent of remyelination was comparable in both treatment groups, suggesting that FTY720 did not affect remyelination in both brain areas. In line with these findings, oligodendrocyte numbers, as quantified in OLIG2-stained sections, were comparable in the CCm of FTY720-and vehicle-treated animals (compare Figure 2B) .
We next evaluated the magnitude of astrocyte and microglia activation by measuring the relative area covered by positive immunoreactivity for anti-GFAP and anti-IBA-1. Furthermore, absolute cell numbers were quantified in the respective sections. As demonstrated in Figure 3A , both analyses revealed that severe astrocytosis was evident after acute demyelination. Astrocytosis was still clearly evident 11 days after cessation of acute demyelination, highlighting the important role of astrocytes for remyelination processes (Skripuletz et al., 2013) . Comparably, the relative area covered by positive immunoreactivity for anti-IBA-1 as well as absolute numbers of microglia cells dramatically increased during the 5 weeks of cuprizone treatment protocol. In contrast to astrocytosis, microgliosis returned almost to control levels during the 11 days of recovery period (compare Figure 3A and B). Most importantly, FTY720 treatment did not affect either of the gliosis parameters during the observation period. Furthermore, the relative area covered per microglia cell, an indirect measurement of microglia hypertrophy, was comparable in FTY720-and vehicle-treated animals (P = 0.17; Figure 3B , lower right side). These results strongly suggest that the activation of astrocytes and microglia was not affected by FTY720 treatment, at least on the morphological level.
While it has been suggested that remyelination protects axons from demyelination-associated axon degeneration (Irvine and Blakemore, 2008) , results of a recent study suggest that even after completed remyelination, axonal degeneration continues to progress at a low level (Manrique-Hoyos et al., 2012) . To address this point, slides were processed for IHC using anti-APP antibodies which is a frequently used marker to detect acute, ongoing axonal damage (Bitsch et al., 2000; Herrero-Herranz et al., 2008) . As demonstrated in Figure 3C , low numbers of APP + spheroids were detectable in control animals, whereas a significant accumulation was evident after acute cuprizone-induced demyelination. Interestingly, despite significant myelin repair, numbers of APP + spheroids were still increased 11 days after acute demyelination. Notably, numbers of APP + spheroids were dramatically lower in FTY720-treated compared with vehicle-treated mice. Precisely, 215 spheroids·mm −2 were detectable in vehicletreated animals compared with 104 spheroids·mm −2 in FTY720-treated animals (P < 0.01). Distinct isoforms of APP can be expressed by activated glia cells, among astrocytes (Gehrmann et al., 1995) . To confirm that APP + spheroids are indeed an accurate marker for axonal damage in this model, we performed immunofluorescence double labelling and analysed the stained sections by confocal laser scanning microscopy. As shown in Figure 3C (lower part), APP + spheroids do not colocalize with cell nuclei and are regularly flanked by neurofilaments, indicating their axonal origin. In summary, our data clearly showed that ongoing axonal damage after a demyelinating event is effectively suppressed by FTY720 application.
Our results indicated that FTY720 might exert neuroprotective effects in acutely demyelinated lesions. In the next set of experiments, we investigated whether (i) acute axonal damage was still ongoing in chronic lesions; and (ii) whether FTY720 was able to ameliorate this chronic, neurodegenerative process. To this end, animals were fed cuprizone for 12 weeks to induce chronic lesions. Becasuse remyelination is limited after prolonged cuprizone exposure (Lindner et al., 2009; Zhou et al., 2012) , animals were allowed to recover for 28 days in these experiments. As demonstrated in Figure 4A , severe demyelination was seen in the CCm after chronic cuprizone exposure. In line with findings from Lindner et al. (2009) , significant remyelination was observed -but delayed -after chronic cuprizone exposure. Specifically, recovery Note that acute axonal damage is significantly lower in animals treated with FTY720 for 11 days after acute cuprizone-induced demyelination. Further note that APP + spheroids do not colocalize to cell bodies but are flanked by axonal neurofilaments (red arrows in the lower part of C) (black scale bar: 100 μm; white scale bar: 10 μm). *P < 0.05; ** P < 0.01; ***P < 0.001, significantly different as indicated.
occurred from 5 to 63% in PLP-stained and from 3 to 34% in LFB-stained sections. FTY720-treated animals did not show higher remyelination capacity in any of these stains in this chronic experimental setting. These findings are supported by quantification of oligodendrocyte cell numbers, where comparable amounts were detected in both experimental groups ( Figure 4B ). Mild astrogliosis and microgliosis were evident after chronic cuprizone exposure, although at lower levels as compared with acute lesions (data not shown).
APP
+ spheroids were still present in chronic lesions, although fewer such signs of acute axonal damage were found, compared with active lesions (215 vs. 43 spheroids per mm 2 ). Comparably, significant numbers of spheroids were detectable after 28 days of recovery. Most importantly, numbers of APP + spheroids were significantly lower in FTY720-treated compared with vehicle-treated mice ( Figure 4C ). In line with this finding, NF-200 staining intensity was significantly increased in FTY720 compared with Note that acute axonal damage is significantly lower and that axonal density is preserved in FTY720-treated animals after chronic cuprizone exposure (scale bar A and C: 100 μm; scale bar B: 30 μm; scale bar D: 200 μm). *P < 0.05, significant effect of FTY720.
vehicle-treated animals (see Figure 4D ) demonstrating that FTY720 preserved axonal integrity not just in acute, but also in chronic, lesions.
Discussion
FTY720 is the first oral disease-modifying therapy to be approved for the treatment of relapsing-remitting MS (Kipp and Amor, 2012) . In line with observations from preclinical studies where FTY720 was effective in the autoimmune MS model EAE (Fujino et al., 2003; Papadopoulos et al., 2010; Choi et al., 2011) , subsequent clinical trials have clearly demonstrated that FTY720 significantly reduced clinical and MRI disease activity in relapsing-remitting MS patients (Devonshire et al., 2012) . Besides the reported antiinflammatory effects, which address the focal aspect of the disease, it has been suggested that FTY720 also exerts protective effects directed against diffuse pathology. This assumption is based on the observation that FTY720 significantly reduced the loss of brain volume compared with placebo treatment. Subgroup analyses confirmed these effects, irrespective of the presence/absence of gadolinium-enhancing lesions, T2 lesion load, previous treatment status or level of disability . Furthermore, FTY720 significantly reduced the risk of disability progression over a 24-month follow-up period (Kappos et al., 2010) . A third, pivotal phase III trial -the INFORMS study -is ongoing in patients with primary progressive MS. FTY720 might offer distinct advantages to patients with this type of MS that is characterized by prominent neurodegeneration and for which an effective therapy is sorely needed (Aktas et al., 2010) .
As discussed in the introduction, S1P receptors, the designated interaction partners of phosphorylated FTY720, are expressed in the brain by a variety of cell types including oligodendrocytes (Jaillard et al., 2005) , neurons (Kimura et al., 2007) and astrocytes (Wu et al., 2008; Van Doorn et al., 2010) . Results of recent studies have shown that a disturbance and/or alterations in S1P signalling may contribute to neuropathological disorders, including MS. Fischer et al. were able to demonstrate that sphingosine kinase 1, one of the two kinases known to be able to activate FTY720, is up-regulated in activated astrocytes (Fischer et al., 2011) . In the same study, they further observed an up-regulation of the S1P receptor subtype 3, which is in line with the findings from Van Doorn et al. (2010) . A comparable dynamic alteration of S1P signalling in MS lesions has been observed by others including expression changes of astrocytic S1P 1 receptors and oligodendrocytic S1P5 receptors (Van Doorn et al., 2010; Brana et al., 2014) , a shift to a higher phospholipid and lower sphingolipid content in the normal appearing white and grey matter (Wheeler et al., 2008) or higher S1P concentrations in the cerebrospinal fluid of relapsing-remitting MS patients (Kulakowska et al., 2010) . The neuroprotective spectrum of FTY720 has been illustrated in various animal models including models for MS (Al-Izki et al., 2011; Kim et al., 2011 ), Alzheimer's disease (Hemmati et al., 2013) , ischaemic stroke (Hasegawa et al., 2010; Liu et al., 2013) , spinal cord injury (Lee et al., 2009 ), Huntington's disease (Di Pardo et al., 2014) or Rett syndrome (Deogracias et al., 2012) . Although it is not easy to separate anti-inflammatory effects from neuroprotective ones, it is obvious that FTY720 exerts beneficial effects beyond its immune-modulatory function. Preservation of axons, which is an intriguing aspect of neuroprotection, is frequently linked to remyelination (Smith et al., 1979; Kornek et al., 2000; . Indeed, results from several studies suggested that FTY720 might boost remyelination and by this regenerative function might exert neuroprotection. Oligodendrocytes express functionally active S1P receptors (Jung et al., 2007) , FTY720 modulates human oligodendrocyte progenitor process extension (Miron et al., 2008b) and rescues human oligodendrocytes from serum and glucose deprivation-induced apoptosis (Miron et al., 2008a) . Anti-apoptotic effects of FTY720 have also been described in oligodendrocyte progenitor cell cultures (Coelho et al., 2007) . These results indicate that FTY720 modulates maturity-and species-specific oligodendrocyte membrane dynamics and survival responses that might be directly relevant for myelin integrity. This attractive concept gained momentum following the recent observations that FTY720 enhances remyelination in organotypic slice cultures (Miron et al., 2010) . Contradictory to these promising in vitro results, remyelination was not affected by FTY720 treatment in two independent studies after acute cuprizone-induced demyelination (Hu et al., 2011; Kim et al., 2011) or focal demyelination induced by lysophosphatidylcholine injection into the rat spinal cord (Hu et al., 2011) . As a consequence, the effects of FTY720 on myelin repair have been questioned. Our results are in line with previous studies using the cuprizone model as a remyelination tool (Kim et al., 2011) . After acute cuprizoneinduced demyelination, an experimental setting with robust endogenous remyelination capacity, FTY720 was only modestly able to accelerate this spontaneous remyelination process. While recovery of LFB staining intensity was slightly better in FTY720-treated animals, PLP immunoreactivity was comparable with that observed after acute cuprizone-induced demyelination (see Figure 2) . In our study, we extended the analysis of remyelinating FTY720 effects by investigating myelin recovery after chronic cuprizone exposure, an experimental paradigm where endogenous remyelination is significantly impaired Lindner et al., 2009) . In line with our findings after acute demyelination, remyelination occurred to the same magnitude in vehicle-and FTY720-treated animals. This prompts the conclusion that FTY720 does not have the capacity to induce remyelination in the cuprizone model when treatment is initiated after lesion formation. Whether this holds true for other experimental paradigms and, thus, is relevant for MS needs to be clarified in future studies.
Although remyelination per se is neuroprotective, the absence of promyelinating FTY720 effects does not necessarily exclude a neuroprotective property. Some important new aspects of the relationship between remyelination and acute axonal damage have recently been established using the cuprizone model. Following cessation of cuprizone treatment (5 weeks), animals showed an initial recovery of locomotor performance. However, long after remyelination was completed (approximately 6 months after the last demyelinating episode), locomotor performance again declined in remyelinated animals compared with age-matched controls (Manrique -Hoyos et al., 2012) . This study clearly highlights that remyelination and axonal degeneration might occur independently from each other. In the current study, we demonstrated that 11 days after acute cuprizone-induced demyelination, acute axonal damage was still ongoing. This feature was significantly ameliorated by FTY720. Furthermore, we demonstrated that axonal degeneration is as well ongoing in chronic lesions, although to a lower extent. A greater extent of acute axonal damage in active, compared with chronic, lesions is a well-known phenomenon. In myelin oligodendrocyte glycoprotein-induced progressive EAE in mice, the highest incidence of acute axonal injury is present during active demyelination, whereas low but significant axonal injury was observed in inactive demyelinated plaques (Kornek et al., 2000) . The patterns of axonal pathology in chronic active EAE are qualitatively and quantitatively comparable with those found in MS (Kuhlmann et al., 2002) . Importantly, FTY720 also ameliorated this 'slow-burning' tissue destruction in chronically demyelinated lesions.
In our study, we have investigated the occurrence of acute axonal damage assessed by IHC for APP which is produced in neuronal perikarya and accumulates at sites of recent axon transection or damage. It is important to note that acute axonal damage is more likely to be a reversible process (Shriver and Dittel, 2006; Nikic et al., 2011) , and thus, a potential target for therapy in MS. Our observation that FTY720 decreased the number of acutely damaged axons raises critical questions as to which underlying mechanisms and factors contribute to such a protective effect. Understanding these effects would help to understand how FTY720 reduces brain atrophy and prevents progression of clinical disability.
